

# PCPA UPDATE

April - June 2023

# Q2 2023

A high-level summary of the quarterly pan-Canadian Pharmaceutical Alliance (pCPA) activity & processes

## pCPA ACTIVITY



**Initiated 25 files**  
(Q1 2023: 26 files)



**Completed 21 files**  
(Q1 2023: 23 files)




**Closed 3 files**  
(Q1 2023: 3 files)



**Declined 1 file**  
(Q1 2023: 1 file)


## FILES UNDER CONSIDERATION



### Insights

- CADTH issued 12 positive and 1 'Do Not Reimburse' recommendations in Q2 2023.
- pCPA initiated negotiations for 25 files during the quarter. The volume of files under consideration decreased to 33 by the end of the quarter, the lowest volume seen in the past year.
- Meanwhile, the average days under consideration increased from 182 in Q1 to 225 days this quarter.
- Over the course of 2023, the volume of files under consideration has steadily declined from 48 files in January down to 33 files in June. The decrease has largely been driven by the initiation of negotiations for oncology products coupled with fewer oncology recommendations from CADTH.

## FILES UNDER NEGOTIATION




### Insights


- pCPA initiated 25 files in Q2 2023 while it completed 21, closed 3, and did not pursue negotiations for 1.
- The volume of files under active negotiation peaked in February with 45 active files. That same month saw 45 files under consideration at pCPA, demonstrating the high volumes of products working through the system.
- The volume of files under active negotiation was consistent throughout Q2 with an average of 36 files under active negotiation.
- The average time under negotiation has remained fairly consistent throughout 2023, with an average of 115 days under negotiation. This represents a decrease from the average days under negotiation in the latter half of 2022, 150 days.

## pCPA CAPACITY

### Volume of Processed Files



### Long Term Files



### Insights

- pCPA completed 21 negotiations (9 oncology, 10 non-oncology, and 2 "other") with LOIs in Q3 2023, closed 3 non-oncology negotiations without LOIs, and declined to negotiate 1 oncology file.
- The overall volume of files adjudicated by pCPA has been higher in the first half of 2023 than the latter half of 2022, with the vast majority of files completing with LOI.
- pCPA declined to negotiate 1 file this quarter, Idhifa, which received negative recommendations from both CADTH and INESSS in 2019.
- Of the 3 files closed this quarter, all received positive recommendations from INESSS, and 2 of the 3 received positive recommendations from CADTH.
- The number of files under consideration for >6 months hit a high of 18 in May 2023. Files under active negotiation for over 12 months have stayed at a constant of two since March after dipping to 0 in December.

